XML 29 R35.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
GENERAL (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Net loss $ 27,337 $ 22,599 $ 37,066  
Accumulated deficit 358,178 330,841    
Net cash used in operating activities $ 27,888 $ 13,291 $ 30,658  
Percentage of workforce reduction from restructuring activities 35.00%      
Research and Development Collaboration and Licensing Agreement        
Upfront payment received $ 10,000     $ 10,000
Potential milestone compensation 200,000     250,000
Preclinical milestone compensation       $ 23,000
Amount of investment in Compugen $ 12,000